Can you take Influenza virus vaccine, h5n1 with Vivimusta?

The influenza virus vaccine, H5N1, inactivated in influenza virus vaccine, h5n1 has a moderate potential interaction with Bleeding Associated with Coagulation Defect.

As with other intramuscular injections, this vaccine should be given with caution in individuals with bleeding disorders, such as hemophilia or on anticoagulation therapy, to avoid the risk of hematoma following the injection.

The bendamustine in Vivimusta has a moderate potential interaction with Bone Marrow Depression/Low Blood Counts.

Adult and pediatric patients treated with bendamustine have experienced Infection, including pneumonia, sepsis, septic shock, and death. Patients with myelosuppression following treatment with bendamustine hydrochloride are more susceptible to infections. Therapy with bendamustine should be administered cautiously in patients with compromised bone marrow reserve. Monitor complete blood counts, including leukocytes, platelets, hemoglobin (Hgb), and neutrophils frequently.

The bendamustine in Vivimusta has a moderate potential interaction with Bone Marrow Depression/Low Blood Counts.

Infection, including pneumonia, sepsis, septic shock, hepatitis, and death has occurred in adult and pediatric patients treated with bendamustine. Care should be exercised when using this drug in patients whose bone marrow reserve may be severely depressed as these patients could be more susceptible to infections. Patients treated with this drug are at risk for reactivation of infections including (but not limited to) hepatitis B, cytomegalovirus, Mycobacterium tuberculosis, and herpes zoster. It is recommended to advise patients with myelosuppression following treatment with this agent to contact a physician immediately if they have symptoms or signs of infection. Before starting treatment, patients should undergo appropriate measures (including clinical and laboratory monitoring, prophylaxis, and treatment) for infection and infection reactivation risks.

The influenza virus vaccine, H5N1, inactivated in influenza virus vaccine, h5n1 has a major potential interaction with Guillain-Barre Syndrome.

Careful consideration of the potential risks and benefits should be given before deciding to give the influenza virus vaccine H5N1 to any patient who developed GBS within 6 weeks of receipt of a prior influenza vaccine.

The influenza virus vaccine, H5N1, inactivated in influenza virus vaccine, h5n1 has a moderate potential interaction with Immunodeficiency.

If Influenza Virus Vaccine, H5N1, is administered to immunocompromised patients, including individuals receiving immunosuppressive therapy, the expected immune response may not be obtained.

The bendamustine in Vivimusta has a moderate potential interaction with Infection.

Infection, including pneumonia, sepsis, septic shock, hepatitis, and death has occurred in adult and pediatric patients treated with bendamustine. Care should be exercised when using this drug in patients whose bone marrow reserve may be severely depressed as these patients could be more susceptible to infections. Patients treated with this drug are at risk for reactivation of infections including (but not limited to) hepatitis B, cytomegalovirus, Mycobacterium tuberculosis, and herpes zoster. It is recommended to advise patients with myelosuppression following treatment with this agent to contact a physician immediately if they have symptoms or signs of infection. Before starting treatment, patients should undergo appropriate measures (including clinical and laboratory monitoring, prophylaxis, and treatment) for infection and infection reactivation risks.

The bendamustine in Vivimusta has a major potential interaction with Liver Disease.

Bendamustine injection should be used with caution in patients with hepatic impairment. Bendamustine injection should not be used in patients with moderate (AST or ALT 2.5 to 10 X ULN and total bilirubin 1.5 to 3 X ULN) or severe (total bilirubin greater than 3 X ULN) hepatic impairment.

The bendamustine in Vivimusta has a major potential interaction with Renal Dysfunction.

Bendamustine injection should be used with caution in patients with mild or moderate renal impairment. Bendamustine injection should not be used in patients with CrCL < 40 mL/min.